Showing 1171-1180 of 9130 results for "".
Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvThe Future of Customized Treatments Within the Atopic Dermatitis Pipeline
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/the-future-of-customized-treatments-within-the-atopic-dermatitis-pipeline/37165/Practical Dermatology Editorial Board member Peter Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine, discusses the potential impact of new developments in atopic dermatitis research.Research Highlights Disparities in AD Care
https://practicaldermatology.com/programs/practical-dermatology/research-highlights-disparities-in-ad-care/36472/In this episode of DermwireTV, research on socioeconomic disparities in atopic dermatitis care; new information on guselkumab for scalp psoriasis in diverse skin tones; the impact of air quality on dermatitis; and a C-Suite Chat with Anastasia Georgievskaya, founder of Haut.AI.Combination Therapy for Vitiligo Treatment
https://practicaldermatology.com/series/updates-vitiligo/combination-therapy-vitiligo-treatment/26561/Dr. Natasha Atanaskova Mesinkovsa, Vice Chair for Clinical Research at the University of California, Irvine, talks with Practical Dermatology about phototherapy in combination with topical JAK inhibitors for vitiligo. Dr. Mesinkovska also discusses the efficacy of at-home devices and mortality ratesDermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinUnplugged: Cutting-Edge Aesthetic Medicine
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/unplugged-cutting-edge-aesthetic-medicine/20142/Jeanine Downie, MD shares pearls from her presentation in the Unplugged session she co-chaired with José Montes, MD. She discusses some of the latest tightening devices for the face, neck, and body, including EmFace, Zaffiro, and Sofwave. Plus, she reviews topics presented by colleagues throughout tEstrogen and Skin: What Can We Do
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/estrogen-and-skin-what-can-we-do/20123/There’s accumulated evidence that depletion of estrogen with age contributes to the visible signs of skin aging. But dermatologists haven’t had many treatment options—until now. Joel L. Cohen, MD addresses the latest developments in care for estrogen deficient skin.Challenging Cases
https://practicaldermatology.com/conferences/maui-derm-2022/challenging-cases/20054/Seemal R. Desai, MD was part of the Challenging Cases session on everything from new infectious diseases to challenging surgical and aesthetic complications. He says dermatologists play an important role in saving and transforming patients' lives.Hormonal Acne Treatment Options
https://practicaldermatology.com/conferences/maui-derm-2022/hormonal-acne-treatment-options/20053/All acne is hormonal acne, says Julie C. Harper, MD. She discusses her approach to treating acne in preadolescents, adolescents, and male and female patients. From the role of oral contraceptives for women to the new topical clascoterone option, she says there are a number of safe and effective treaDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility study